Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal versus intramuscular H5N8 zoonotic influenza vaccine dose-selection trial in adults aged 40 to 80 years
2026-525756-28-00Phase 2Authorised
- Sponsor
- University of Antwerp
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of aH5N8c in Avian Influenza (AI) (4 arms), sponsored by University of Antwerp. Primary endpoints: HI antibody titers expressed as group GMT ratio 1 month after the second dose and HI seroconversion rates 1 month after the second dose. Planned start Oct 2026; status: authorised.
02
Drugs
aH5N8c
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on 2026-525756-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525756-28-00.